Tevogen Bio (NASDAQ:TVGN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Tevogen Bio Price Performance

Shares of NASDAQ:TVGN opened at $1.07 on Tuesday. Tevogen Bio has a 12-month low of $0.26 and a 12-month high of $6.95. The business has a 50-day moving average price of $1.36 and a 200 day moving average price of $1.17.

Insider Transactions at Tevogen Bio

In related news, insider Neal Flomenberg sold 70,384 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56. Following the transaction, the insider now owns 3,898,828 shares of the company’s stock, valued at $4,249,722.52. This trade represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 173,542 shares of company stock valued at $192,827. 56.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tevogen Bio

Several institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in Tevogen Bio during the 4th quarter worth about $38,000. JPMorgan Chase & Co. grew its stake in Tevogen Bio by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after purchasing an additional 16,695 shares in the last quarter. Barclays PLC raised its stake in Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after acquiring an additional 12,847 shares during the period. XTX Topco Ltd bought a new stake in Tevogen Bio in the fourth quarter valued at $55,000. Finally, HGC Investment Management Inc. bought a new position in Tevogen Bio in the 3rd quarter worth approximately $82,000.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.